

Amendments to the Claims

Claim 1. (currently amended): An allogeneic immunotherapeutic agent for ~~the treatment of prostate cancer comprising~~ eliciting an immunological response against prostate cancer, wherein the immunological agent comprises three human prostate cell lines from three different sources, wherein said sources are selected from the group consisting of:

- (a) normal prostate human tissue,
- (b) primary prostate human tissue, and
- (c) metastatic prostate human tissue,

at least and wherein one to three of said human prostate cell lines is non-cancerous.

Claims 2-10. (canceled).

Claim 11. (currently amended): An allogeneic immunogenic composition comprising [[an]] the immunotherapeutic agent of claim 1, combined with a vaccine adjuvant selected from the group consisting of BCG, *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and non-specific adjuvants.

Claim 12. (currently amended): An immunogenic composition comprising [[an]] the immunotherapeutic agent of claim 1, combined with a vaccine adjuvant, wherein [[the]] said adjuvant is a mycobacterial preparation.

Claims 13-24. (canceled).

Claim 25. (new) The allogeneic immunotherapeutic agent of claim 1, wherein said cell lines are selected so as to maximize haplotype mismatch.

Claim 26. (new) The allogeneic immunotherapeutic agent of claim 1, wherein said cell lines derived from primary and metastatic prostate human tissue are rendered replication-incompetent by irradiation.